-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
A few days ago, it was reported that AstraZeneca and Inovio had signed a six-year cooperation development agreement with human papillomavirus-related DNA cancer vaccines, which has been cancelled
In a document published by the US Securities Exchange, Inovio announced that AstraZeneca's Medimmune Limited has terminated the development plan of INO-3112, which is a vaccine candidate called MEDI0457
When the two biotech companies first reached a deal in 2015, Medimmune acquired the rights to INO-3112, a drug designed to target cancers caused by human papillomavirus types 16 and 18
INO-3112's cancellation of cooperation does not mean that the two companies have completely disconnected.
In addition, Inovio has also made progress in the ongoing battle against COVID-19 and other infectious diseases
In terms of COVID-19, Inovio has advanced its vaccine candidate to phase III studies
At the same time, the vaccine has also received support from the World Health Organization (WHO) and approved its Phase III trials in Colombia, the Philippines and Mali
Reference source: Inovio and AstraZeneca Terminate Six-Year-Old DNA Cancer Vaccine Program